JAMA Neurology, 70(7), 883890
The acylation allows it to bind albumin, extending its plasma half-life to approximately 13 hours compared to native GLP-1's half-life of roughly 2 minutes [2]
Plaintiffs allege that the manufacturers failed to warn of this risk and are liable for failure to warn, design defect, and breach of warranties
Zepbound (tirzepatide) weekly injection is a dual GIP/GLP-1 medicine also FDA-approved for chronic weight management in adults
We offer transparent monthly pricing with no hidden copays, deductibles, or surprise insurance denials
Clinical trial data raised concerns about thyroid tumors in laboratory studies, yet drug makers continued to market these drugs without adequately warning consumers